Bio Nano Consulting targets US biotechnology market

4 Oct 2010

Bio Nano Consulting (BNC), a joint venture of Imperial College London and University College London, has commenced a US tour meeting biotechnology and pharmaceutical leaders. BNC is aiming to promote nanotechnology partnerships with US biotechnology companies.

Dr David Sarphie, BNC’s CEO commented: “BNC has successfully delivered a number of contracts in the US where UK innovation and knowledge has helped solve some real-world problems for US clients. We see significant opportunities for US expansion due to the increasing pressures to reduce costs, increase speed to market and decrease attrition rates.

“The US visit to San Francisco and Boston aims to highlight to a wider life science audience how nanotechnology can help improve product development. This includes increasing the knowledge of how drugs really interact with their targets, by solving formulation problems to increase bioavailability, and to promoting BNC’s unique services in accessing academic research and expertise combined with a strong commercial imperative. We believe that BNC’s services provide a win-win scenario by solving client problems and also ensuring academic expertise has commercial relevance.”

Planned activities include:

Tuesday 5 October, San Francisco.
8:30 – 10:30. Breakfast Event ‘Nanotechnology in Drug Discovery’
11:30 – 13:30. Radio Interviews with Dr Moira Gunn on BioTech Nation on NPR.

Thursday 7 October, Boston, MA.
16:00 – 19:30. Event: ‘Nanotechnology in Drug Discovery and Development’, British Consulate General, 1 Main St, Cambridge MA.

20:30. Speakers & special guest dinner. Top of the Hub, Prudential Centre, Boston. Proposed Guests: Dr Bruce Pratt, Genzyme; Dan Passerie, CEO Curis Inc; Pepper Denman, GE Healthcare; Dr Gunther Winkler, Biogen Idec.


To top